Biopharmaceutical company Gilead Sciences (NASDAQ: GILD) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 4.7% year on year to $7.93 billion. On the other hand, the company’s full-year revenue guidance of $29.8 billion at the midpoint came in 1.2% below analysts’ estimates. Its non-GAAP profit of $1.86 per share was 1.9% above analysts’ consensus estimates.

Is now the time to buy GILD? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Gilead Sciences ended the fourth quarter with results that exceeded Wall Street revenue expectations, yet the market responded negatively as investors focused on guidance and margin pressures. Management cited strong growth in its HIV business, including a 53% increase in the HIV prevention portfolio and rapid uptake of the new YES2GO injectable, as key drivers. CEO Daniel O’Day noted, “YES2GO is a transformative medicine that we expect to drive durable, steady, and long-term growth in our HIV prevention business.” However, continued headwinds in cell therapy and a notable drop in operating margin from last year contributed to investor concerns.

Looking into 2026, Gilead Sciences’ guidance reflects optimism in several late-stage product launches and the expanding reach of its HIV portfolio. Management is banking on YES2GO’s broadening access, multiple upcoming regulatory milestones, and the launch of new therapies in both oncology and liver disease. CFO Andrew Dickinson emphasized that while policy-related pricing headwinds are expected, underlying business strength remains, stating, “Absent these updates, our full-year growth would be in the range of 6% to 7%.” The company also highlighted a robust clinical pipeline with up to ten new launches possible through 2027.

Key Insights from Management’s Remarks

Management attributed fourth quarter momentum to robust HIV franchise growth, commercial execution of new launches, and progress in the oncology portfolio, while flagging ongoing competitive challenges in cell therapy.

• HIV portfolio strength: Fourth quarter growth was powered by increased demand for Biktarvy and Descovy, with YES2GO’s launch accelerating the shift toward long-acting injectable prevention options. Management noted YES2GO achieved 90% payer coverage well ahead of target, expanding patient access and awareness through a direct-to-consumer campaign.
• Liver disease momentum: The liver franchise saw continued adoption of Libdelzi, particularly in primary biliary cholangitis, benefiting from a competitor withdrawal and helping Gilead gain more than 50% market share in second-line PBC.
• Oncology pipeline progress: Trodelvy maintained growth in metastatic breast cancer and is positioned for expansion into first-line triple-negative breast cancer, supported by positive clinical trial updates and inclusion in updated treatment guidelines.
• Cell therapy headwinds: Cell therapy revenue declined as anticipated, due to heightened competition and clinical trial enrollment impacting volumes, with management expecting these pressures to persist into 2026.
• Expense discipline: Operating expenses were managed tightly, with R&D and SG&A both down year-over-year, helping offset some margin pressure and supporting ongoing investment in new launches.

Drivers of Future Performance

Gilead Sciences expects new product launches and expanded indications to drive growth, though pricing and competitive pressures remain key themes for 2026.

• YES2GO and HIV prevention expansion: Management expects YES2GO to become a leading product in HIV prevention, with growth supported by expanded access, targeted awareness campaigns, and strategies to improve patient persistency and refill rates. However, initial cannibalization of Descovy is anticipated to be limited, with both brands expected to grow in the near term.
• Oncology launches and pipeline readouts: The company is preparing for multiple potential launches, including Trodelvy in first-line triple-negative breast cancer and Anidocel in multiple myeloma, alongside key Phase III trial updates in lung and endometrial cancers. These are expected to strengthen Gilead’s oncology presence and diversify revenue streams.
• Policy and pricing headwinds: Drug pricing reforms and changes to government reimbursement policies are expected to create a 2% headwind to HIV growth. Management also cited competitive dynamics in cell therapy and potential shifts to lower-priced channels as risks that could impact top-line performance.

Catalysts in Upcoming Quarters

In coming quarters, the StockStory team will be watching (1) the pace of YES2GO adoption and refill persistence, (2) regulatory and commercial progress for Trodelvy and Anidocel launches, and (3) the impact of policy-driven pricing headwinds on HIV and liver franchises. Execution across these milestones will determine if Gilead can maintain growth despite external pressures.

Gilead Sciences currently trades at $145.81, down from $147.80 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

High Quality Stocks for All Market Conditions

If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.

Don’t wait for the next volatility shock. Check out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.